Psyence Group reposted this
Proud to be in collaboration with iNGENū CRO on our Phase llb clinical trial developing a safe, responsible, FDA-approved non-synthetic, nature-derived psilocybin candidate to treat Adjustment Disorder in oncology patients in a Palliative Care context.
Here’s why leading US biotechs are choosing Australia as their destination to conduct clinical trials. 🇦🇺 🇺🇸 Working with an Australian CRO means you still experience the value of a premium quality clinical trial - but with two major benefits: 🧿Cost-reduction: You can expect up to a 70% reduction in costs compared to those offered by CROs in the US. That’s a significant reduction in the capital your firm has to raise. But don’t make the mistake of thinking that cost and quality are inversely related. iNGENū is able to deliver an equivalently high quality outcome as you could expect in the US. 🧿Faster application lodgement: In Australia, the average trial application can be lodged within 8 weeks - as opposed to the 12+ MONTH timeline you can expect in the US. For US biotechs that choose to work with Australian CROs, this leads to time savings of 1.5+ years - enabling you to get your Phase 1 trial data much quicker than in the US. So, by leveraging the benefits of working with an Australian CRO to conduct your clinical trials, you’re able to: - Commence your clinical trial SIGNIFICANTLY faster than in the US, and - Avoid many of the high-costs you would conventionally require when you work with a US-based CRO